Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription 15.04.2024 2 AJR Am J Roentgenol 1 Am J Epidemiol 3 Ann Surg Oncol 1 BMC Cancer 2 Br J Cancer 4 Breast Cancer 1 Breast Cancer (Dove Med Press) 3 Breast Cancer Res 5 Breast Cancer Res Treat 1 Cancer Cell 2 Cancer Lett 1 Cancer Res 2 Clin Breast Cancer 1 Clin Exp Metastasis 1 Curr Treat Options Oncol 1 Exp Cell Res 2 Gene 1 Int J Radiat Oncol Biol Phys 1 J Clin Invest 1 J Clin Oncol 2 J Natl Cancer Inst 2 JAMA 2 Lancet 1 Lancet Oncol 1 Mol Ther Oncol 1 N Engl J Med 1 Nature 1 NPJ Breast Cancer 1 Oncogene 2 PLoS One 1 Radiol Artif Intell 2 Radiol Imaging Cancer 2 Radiology 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. JIRARAYAPONG J, Portnow LH, Chikarmane SA, Lan Z, et al
   High Peritumoral and Intratumoral T2 Signal Intensity in HER2+ Breast Cancers on Preneoadjuvant Breast MRI: Assessment of Associations With Histopathologic Characteristics.
   AJR Am J Roentgenol. 2023 Dec 20. doi: 10.2214/AJR.23.30280.
   PubMed         Abstract available
   
   
2. NGUYEN DL, Greenwood HI, Rahbar H, Grimm LJ, et al
   Evolving Treatment Paradigms for Low-Risk Ductal Carcinoma In Situ: Imaging Needs.
   AJR Am J Roentgenol. 2023 Dec 13. doi: 10.2214/AJR.23.30503.
   PubMed         Abstract available
   
   

   
   Am J Epidemiol

3. PAPANTONIOU K, Hansen J
   Cohort Studies Versus Case-Control Studies on Night-Shift Work and Cancer Risk: The Importance of Exposure Assessment.
   Am J Epidemiol. 2024;193:577-579.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. CHU JJ, Tadros AB, Vingan PS, Assel MJ, et al
   Remote Symptom Monitoring with Clinical Alerts Following Mastectomy: Do Early Symptoms Predict 30-Day Surgical Complications.
   Ann Surg Oncol. 2024;31:3377-3386.
   PubMed         Abstract available
   
   
5. GREENE AJE, Davis J, Moon J, Dubin I, et al
   Determination of Factors Associated with Upstage in Atypical Ductal Hyperplasia to Identify Low-Risk Patients Where Active Surveillance May be an Alternative.
   Ann Surg Oncol. 2024;31:3177-3185.
   PubMed         Abstract available
   
   
6. XIONG M, Young AT, Fernandez A, Jones JS, et al
   Understanding Breast Cancer Surgery Through Tiktok: an Analysis of Video Content and Viewer Engagement.
   Ann Surg Oncol. 2024 Apr 9. doi: 10.1245/s10434-024-15268.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. LIU Z, Li J, Zhao F, Ren D, et al
   Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis.
   BMC Cancer. 2024;24:440.
   PubMed         Abstract available
   
   

   
   Br J Cancer

8. ALEXANDER J, Schipper K, Nash S, Brough R, et al
   Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.
   Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02679.
   PubMed         Abstract available
   
   
9. ARSHAD M, Azad A, Chan PYK, Vigneswara V, et al
   Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
   Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02665.
   PubMed         Abstract available
   
   

   
   Breast Cancer

10. TOKUDA PJK, Mitsuyoshi T, Ono Y, Kishi T, et al
    Acute adverse events of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for early breast cancer in Japan: an interim analysis of the multi-institutional phase II UPBEAT study.
    Breast Cancer. 2024 Apr 12. doi: 10.1007/s12282-024-01577.
    PubMed         Abstract available
    
    
11. DE MOURA A, Loirat D, Vaillant S, Korbi S, et al
    Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
    Breast Cancer. 2024 Apr 10. doi: 10.1007/s12282-024-01565.
    PubMed         Abstract available
    
    
12. SUZUKI K, Morishita S, Nakano J, Okayama T, et al
    Association between quality of life and mortality risk in patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2024 Apr 9. doi: 10.1007/s12282-024-01581.
    PubMed         Abstract available
    
    
13. WATANABE A, Tsunashima R, Kato C, Kitano S, et al
    Investigation of recurrence prediction ability of EndoPredict((R)) using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict((R)) from microarray data from fresh-frozen to FFPE
    Breast Cancer. 2024 Apr 8. doi: 10.1007/s12282-024-01573.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

14. WANG S, Chen Y, Li W, Hao C, et al
    Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients.
    Breast Cancer (Dove Med Press). 2024;16:163-179.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

15. KARIHTALA P, Leivonen SK, Puistola U, Urpilainen E, et al
    Serum protein profiling reveals an inflammation signature as a predictor of early breast cancer survival.
    Breast Cancer Res. 2024;26:61.
    PubMed         Abstract available
    
    
16. ZHANG W, Song X, Jin Z, Zhang Y, et al
    U2AF2-SNORA68 promotes triple-negative breast cancer stemness through the translocation of RPL23 from nucleoplasm to nucleolus and c-Myc expression.
    Breast Cancer Res. 2024;26:60.
    PubMed         Abstract available
    
    
17. WOOLPERT KM, Schmidt JA, Ahern TP, Hjorth CF, et al
    Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
    Breast Cancer Res. 2024;26:59.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

18. ALLSOPP RC, Guo Q, Page K, Bhagani S, et al
    Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study.
    Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07316.
    PubMed         Abstract available
    
    
19. RUKHSANA, Supty AT, Hussain M, Lee Y, et al
    STK3 higher expression association with clinical characteristics in intrinsic subtypes of breast cancer invasive ductal carcinoma patients.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07248.
    PubMed         Abstract available
    
    
20. WANG Y, Sun W, Karlsson E, Kang Lovgren S, et al
    Clinical evaluation of deep learning-based risk profiling in breast cancer histopathology and comparison to an established multigene assay.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07303.
    PubMed         Abstract available
    
    
21. FORTNER RT, Brantley KD, Tworoger SS, Tamimi RM, et al
    Recreational physical activity and breast cancer risk by menopausal status and tumor hormone receptor status: results from the Nurses' Health Studies.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-023-07238.
    PubMed         Abstract available
    
    
22. BRANDAO M, Martins-Branco D, De Angelis C, Vuylsteke P, et al
    Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07275.
    PubMed        
    
    

    
    Cancer Cell

23. LIN CJ, Jin X, Ma D, Chen C, et al
    Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.
    Cancer Cell. 2024;42:701-719.
    PubMed         Abstract available
    
    

    
    Cancer Lett

24. WANG J, Fan P, Shen P, Fan C, et al
    XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer.
    Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846.
    PubMed         Abstract available
    
    
25. LI K, Lin H, Liu A, Qiu C, et al
    SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
    Cancer Lett. 2024;590:216842.
    PubMed         Abstract available
    
    

    
    Cancer Res

26. ZHENG SM, Feng YC, Zhu Q, Li RQ, et al
    MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer.
    Cancer Res. 2024 Apr 9:OF1-OF15. doi: 10.1158/0008-5472.CAN-23-3046.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

27. MICHAELS E, Chen N, Nanda R
    The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
    Clin Breast Cancer. 2024 Mar 6:S1526-8209(24)00061.
    PubMed         Abstract available
    
    
28. D'ALESSANDRO GS, Munhoz AM, Takeuchi FM, Povedano A, et al
    Is Immediate Breast Reconstruction With a Latissimus Dorsi Myocutaneous Flap Safe for Starting Adjuvant Chemotherapy in Patients With Breast Cancer?
    Clin Breast Cancer. 2024 Mar 10:S1526-8209(24)00076.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

29. BHAT V, Piaseczny M, Goodale D, Patel U, et al
    Lung-derived soluble factors support stemness/plasticity and metastatic behaviour of breast cancer cells via the FGF2-DACH1 axis.
    Clin Exp Metastasis. 2024 Apr 6. doi: 10.1007/s10585-024-10284.
    PubMed         Abstract available
    
    

    
    Curr Treat Options Oncol

30. MOLINELLI C, Jacobs F, Nader-Marta G, Borea R, et al
    Ovarian Suppression: Early Menopause and Late Effects.
    Curr Treat Options Oncol. 2024;25:523-542.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

31. SHOME R, Sen P, Sarkar S, Ghosh SS, et al
    Single-cell transcriptomics reveals the intra-tumoral heterogeneity and SQSTM1/P62 and Wnt/beta-catenin mediated epithelial to mesenchymal transition and stemness of triple-negative breast cancer.
    Exp Cell Res. 2024 Apr 5:114032. doi: 10.1016/j.yexcr.2024.114032.
    PubMed         Abstract available
    
    

    
    Gene

32. DEHGHANIAN F, Ghahnavieh LE, Nilchi AN, Khalilian S, et al
    Breast cancer drug resistance: Decoding the roles of Hippo pathway crosstalk.
    Gene. 2024;916:148424.
    PubMed         Abstract available
    
    
33. VOSOOGHI R, Motavalizadehkakhky A, Mansouri A, Mehrzad J, et al
    Investigating the effect of hesperetin on estrogen receptor alpha (ERalpha) expression, phosphorylation and activity in MCF-7 cells.
    Gene. 2024;911:148357.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

34. LOVING BA, Almahariq MF, Sivapalan S, Levitin R, et al
    Newly Diagnosed Mental Health Disorders in Patients with Breast Cancer Receiving Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2024 Apr 4:S0360-3016(24)00445.
    PubMed         Abstract available
    
    

    
    J Clin Invest

35. JOHNSON N
    Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability.
    J Clin Invest. 2024;134:e179325.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

36. RIOS-HOYO A, Cobain E, Huppert LA, Beitsch PD, et al
    Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
    J Clin Oncol. 2024 Apr 9:JCO2302614. doi: 10.1200/JCO.23.02614.
    PubMed        
    
    

    
    J Natl Cancer Inst

37. OMOLEYE OJ, Esserman LJ, Olopade OI
    RE: Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
    J Natl Cancer Inst. 2024;116:627-628.
    PubMed        
    
    
38. VILLY MC, Le Ven A, Le Mentec M, Masliah-Planchon J, et al
    Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants.
    J Natl Cancer Inst. 2024;116:580-587.
    PubMed         Abstract available
    
    

    
    JAMA

39. NAROD SA
    Breast Cancer and Pregnancy in Young BRCA Carriers.
    JAMA. 2024;331:1233-1234.
    PubMed        
    
    
40. BLONDEAUX E, Partridge AH, Lambertini M
    Breast Cancer and Pregnancy in Young BRCA Carriers-Reply.
    JAMA. 2024;331:1234.
    PubMed        
    
    

    
    Lancet

41. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
    Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
    PubMed         Abstract available
    
    
42. EARL HM
    Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
    Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
    PubMed        
    
    

    
    Lancet Oncol

43. VAN DER VOORT A, Louis FM, van Ramshorst MS, Kessels R, et al
    MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2024 Apr 5:S1470-2045(24)00104.
    PubMed         Abstract available
    
    

    
    Mol Ther Oncol

44. LIAO Q, Zhang R, Ou Z, Ye Y, et al
    TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs.
    Mol Ther Oncol. 2024;32:200762.
    PubMed         Abstract available
    
    

    
    N Engl J Med

45. DE BONIFACE J, Filtenborg Tvedskov T, Ryden L, Szulkin R, et al
    Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
    N Engl J Med. 2024;390:1163-1175.
    PubMed         Abstract available
    
    

    
    Nature

46. ABRAHAM JE, Pinilla K, Dayimu A, Grybowicz L, et al
    The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer.
    Nature. 2024 Apr 8. doi: 10.1038/s41586-024-07384.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

47. BAR Y, Keenan JC, Niemierko A, Medford AJ, et al
    Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer.
    NPJ Breast Cancer. 2024;10:27.
    PubMed         Abstract available
    
    

    
    Oncogene

48. BOTTONI L, Minetti A, Realini G, Pio E, et al
    NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells.
    Oncogene. 2024 Apr 10. doi: 10.1038/s41388-024-03025.
    PubMed         Abstract available
    
    

    
    PLoS One

49. ALHASSAN AM
    An improved breast cancer classification with hybrid chaotic sand cat and Remora Optimization feature selection algorithm.
    PLoS One. 2024;19:e0300622.
    PubMed         Abstract available
    
    
50. SLOJEWSKA K, Galbarczyk A, Klimek M, Tubek-Krokosz A, et al
    Higher number of steps is related to lower endogenous progesterone but not estradiol levels in women.
    PLoS One. 2024;19:e0299580.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

51. LARSEN M, Olstad CF, Lee CI, Hovda T, et al
    Performance of an AI System for Breast Cancer Detection on Screening Mammograms from BreastScreen Norway.
    Radiol Artif Intell. 2024 Apr 10:e230375. doi: 10.1148/ryai.230375.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

52. SPRAGUE BL, Nowak SA, Ahern TP, Herschorn SD, et al
    Long-term Mammography Screening Trends and Predictors of Return to Screening after the COVID-19 Pandemic: Results from a Statewide Registry.
    Radiol Imaging Cancer. 2024;6:e230161.
    PubMed         Abstract available
    
    
53. POLAT DS, Nguyen S, Karbasi P, Hulsey K, et al
    Machine Learning Prediction of Lymph Node Metastasis in Breast Cancer: Performance of a Multi-institutional MRI-based 4D Convolutional Neural Network.
    Radiol Imaging Cancer. 2024;6:e230107.
    PubMed         Abstract available
    
    

    
    Radiology

54. LIU Y, Sorkhei M, Dembrower K, Azizpour H, et al
    Use of an AI Score Combining Cancer Signs, Masking, and Risk to Select Patients for Supplemental Breast Cancer Screening.
    Radiology. 2024;311:e232535.
    PubMed         Abstract available
    
    
55. KIM MK, Chang JM
    AI-driven Selection of Candidates for Supplemental Breast Cancer Screening.
    Radiology. 2024;311:e240447.
    PubMed        
    
    

    
    Semin Oncol

56. SOBRINI-MORILLO P, Ravot C, Herledan C, Sanchez-Castellano C, et al
    Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer.
    Semin Oncol. 2024 Feb 22:S0093-7754(24)00003.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.